Pediatric MG Research Grant: Understanding and Treating Myasthenia Gravis in Pediatric and Adolescent Populations
Pediatric MG Research Grant supports investigators studying myasthenia gravis in children and adolescents to improve diagnosis, treatment, long-term outcomes, and quality of life.
Funder: Myasthenia Gravis Foundation of America
Due Dates: October 16, 2026 (LOI, extended; passed) | November 18, 2026 (Invited full applications)
Funding Amounts: Two awards of up to $125,000 each over two years; up to $12,500 per award for indirect costs
Summary: Supports research advancing diagnosis, treatment, outcomes, and quality of life for children and adolescents with myasthenia gravis.
Key Information: Principal investigators must have confirmed faculty status; for-profit and small-business submissions are ineligible.
Description
The Myasthenia Gravis Foundation of America (MGFA) supports research addressing unmet needs in pediatric and adolescent myasthenia gravis (MG). Most pivotal MG therapy trials enrolled few or no children, leaving pediatric treatment largely extrapolated from adult data. Functional measures such as MG-ADL and QMG have also not been formally validated in pediatric populations. The program aims to strengthen evidence for pediatric treatment strategies, safety, and long-term outcomes.
Supported work spans diagnosis and disease characterization, treatment safety and pharmacology, outcome measures and trial readiness, natural history, immunomechanisms, and psychosocial impact. Examples include differentiating juvenile MG from congenital myasthenic syndromes, pediatric dosing and comparative treatment strategies, age-appropriate endpoints, predictors of remission, transition to adult care, and interventions addressing education, development, family functioning, or mental health. Proposals should align with the MGFA research agenda.
